Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century.

Literature DB >> 29708166

Extending the curve: survival of EGFR-mutated lung cancer patients in the 21^st century.

Feliciano Barrón¹, Zyanya Lucia Zatarain-Barrón¹, Andrés F Cardona^2,3, Oscar Arrieta¹.

Abstract

Entities: Disease Gene Species

Year: 2018 PMID： 29708166 PMCID： PMC5906342 DOI： 10.21037/jtd.2018.03.28

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

14 in total

1. Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic?

Authors:
Journal: Ann Oncol Date: 2010-04 Impact factor: 32.976

Review 2. One hundred years of lung cancer.

Authors: Stephen G Spiro; Gerard A Silvestri
Journal: Am J Respir Crit Care Med Date: 2005-06-16 Impact factor: 21.405

3. [National consensus of diagnosis and treatment of non-small cell lung cancer].

Authors: Oscar Arrieta; Enrique Guzmán-de Alba; Luis Felipe Alba-López; Alicia Acosta-Espinoza; Jorge Alatorre-Alexander; José Francisco Alexander-Meza; Silvia Rosa Allende-Pérez; Salvador Alvarado-Aguilar; Margarita E Araujo-Navarrete; Luis Marcelo Argote-Greene; Cinthia Alejandra Aquino-Mendoza; Alma Magdalena Astorga-Ramos; Horacio Austudillo-de la Vega; Alejandro Avilés-Salas; Luis Javier Barajas-Figueroa; Nimbe Barroso-Quiroga; Mónica Blake-Cerda; Paula Anel Cabrera-Galeana; Germán Calderillo-Ruíz; Alma Delia Campos-Parra; Ana María Cano-Valdez; Daniel Capdeville-García; Graciano Castillo-Ortega; Catalina Casillas-Suárez; Patricia Castillo-González; José Francisco Corona-Cruz; María Elma Correa-Acevedo; Séfora Sonciry Cortez-Ramírez; Jhony Alberto de la Cruz-Vargas; Jaime G de la Garza-Salazar; María Dolores de la Mata-Moya; María Eugenia Domínguez-Flores; Hugo Ricardo Domínguez-Malagón; Luis Manuel Domínguez-Parra; Alfredo Domínguez-Peregrina; Jaime Durán-Alcocer; María Isabel Enríquez-Aceves; Abelardo Elizondo-Ríos; Moisés Dante Escobedo-Sánchez; Pablo Espinosa-Mireles de Villafranca; Alberto Flores-Cantisani; Juan Pablo Flores-Gutiérrez; Francisco Franco-Marina; Edwin Efraín Franco-González; Ramón Antonio Franco-Topete; Homero Fuentes-de la Peña; Susana Galicia-Amor; Dolores Gallardo-Rincón; Armando Gamboa-Domínguez; Jorge García-Andreu; Claudia María García-Cuéllar; María Cecilia García-Sancho-Figueroa; Rogelio García-Torrentera; Raquel Gerson-Cwilich; Arturo Gómez-González; León Green-Schneeweiss; María del Rocío Guillén-Núñez; Hilda Gutiérrez-Velázquez; Carlos Ibarra-Pérez; Edgardo Jiménez-Fuentes; Paula Juárez-Sánchez; Alejandro Juárez-Ramiro; Javier Kelly-García; Roberto Kuri-Exsome; Jesús Miguel Lázaro-León; Eucario León-Rodríguez; Sara Llanos-Osuna; Sara Llanos-Osuna; Ulises Loyola-García; José Sullivan López-González; Francisco Javier López y de Antuñano; Marco Antonio Loustaunau-Andrade; Eleazar Omar Macedo-Pérez; Limberth Machado-Villarroel; Manuel Magallanes-Maciel; Luis Martínez-Barrera; Jorge Martínez-Cedillo; Gloria Martínez-Martínez; Alfredo Medina-Esparza; Abelardo Meneses-García; Alejandro Mohar-Betancourt; Jaime Morales Blanhir; José Morales-Gómez; Daniel Motola-Kuba; Marcela Patricia Nájera-Cruz; Carolina del Carmen Núñez-Valencia; María Angélica Ocampo-Ocampo; María Dolores Ochoa-Vázquez; Carlos A Olivares-Torres; Andrés Palomar-Lever; Mario Patiño-Zarco; Rogelio Pérez-Padilla; Yolanda Rocío Peña-Alonso; Alfredo Rafael Pérez-Romo; Mario Aquilino Pérez; Paulo Martín Pinaya-Ruíz; María Adela Pointevin-Chacón; Juan José Poot-Braga; Rodolfo Posadas-Valay; Marcelino Ramirez-Márquez; Ivonne Reyes-Martínez; Julio Robledo-Pascual; Jerónimo Rodríguez-Cid; Carlos Enrique Rojas-Marín; Elizabeth Romero-Bielma; Jaime Ernesto Rubio-Gutiérrez; Julia Angelina Sáenz-Frías; Miguel Angel Salazar-Lezama; Karla Sánchez-Lara; Raúl Sansores Martínez; Patricio Santillán-Doherty; Juan Alejandro-Silva; José Luis Téllez-Becerra; Vinicio Toledo-Buenrostro; Luis Torre-Bouscoulet; Laura Torecillas-Torres; Marineé Torres; Víctor Tovar-Guzmán; Jenny Georgina Turcott-Chaparro; Jesús Javier Vázquez-Cortés; María Eugenia Vázquez-Manríquez; Natalia Vilches-Cisneros; José Felipe Villegas-Elizondo; Mauro M Zamboni; Jesús Zamora-Moreno; Juan W Zinser-Sierra
Journal: Rev Invest Clin Date: 2013-03 Impact factor: 1.451

4. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Authors: Yi-Long Wu; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Fumito Tsuji; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Sashi Nadanaciva; Rickard Sandin; Tony S Mok
Journal: Lancet Oncol Date: 2017-09-25 Impact factor: 41.316

5. A new initiative on precision medicine.

Authors: Francis S Collins; Harold Varmus
Journal: N Engl J Med Date: 2015-01-30 Impact factor: 91.245

6. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

Authors: Helena A Yu; Shaozhou K Tian; Alexander E Drilon; Laetitia Borsu; Gregory J Riely; Maria E Arcila; Marc Ladanyi
Journal: JAMA Oncol Date: 2015-10 Impact factor: 31.777

7. Global cancer statistics, 2012.

Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702

Review 8. Osimertinib: First Global Approval.

Authors: Sarah L Greig
Journal: Drugs Date: 2016-02 Impact factor: 9.546

9. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

Authors: Toshiyuki Hirano; Hiroyuki Yasuda; Tetsuo Tani; Junko Hamamoto; Ayano Oashi; Kota Ishioka; Daisuke Arai; Shigenari Nukaga; Masayoshi Miyawaki; Ichiro Kawada; Katsuhiko Naoki; Daniel B Costa; Susumu S Kobayashi; Tomoko Betsuyaku; Kenzo Soejima
Journal: Oncotarget Date: 2015-11-17

10. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors: Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal: N Engl J Med Date: 2017-11-18 Impact factor: 91.245

3 in total

1. EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).

Authors: Alejandro Ruiz-Patiño; Christian David Castro; Luisa María Ricaurte; Andrés F Cardona; Leonardo Rojas; Zyanya Lucia Zatarain-Barrón; Beatriz Wills; Noemí Reguart; Hernán Carranza; Carlos Vargas; Jorge Otero; Luis Corrales; Claudio Martín; Pilar Archila; July Rodriguez; Jenny Avila; Melissa Bravo; Luis Eduardo Pino; Rafael Rosell; Oscar Arrieta
Journal: Target Oncol Date: 2018-10 Impact factor: 4.493

2. Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.

Authors: Ali S Abdelhameed; Adnan A Kadi; Mohamed W Attwa; Haitham AlRabiah
Journal: PLoS One Date: 2019-04-04 Impact factor: 3.240

3. Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation.

Authors: Mohamed W Attwa; Adnan A Kadi; Ali S Abdelhameed
Journal: RSC Adv Date: 2018-11-19 Impact factor: 4.036

3 in total